Radioactive injection takes on tough pancreatic cancer in early trial
NCT ID NCT06278454
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and check for side effects, while also watching for signs that tumors shrink. It is too early to know if this approach will work better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NRT6008 injection (a radioactive drug) plus standard chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX)
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors or slows progression in people with advanced pancreatic cancer that cannot be removed by surgery.
What could go wrong
This is a very early Phase I trial with only 58 participants, so the main goal is safety and finding the right dose—not yet proving it works. The radioactive drug may cause side effects like fatigue or damage to nearby organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, China
Contact
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact
Contact
-
Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact
Contact
-
Shanghai Changhai Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Contact
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Contact
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, China
Contact
Contact